Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults

TY - JOUR

T1 - Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults

AU - Mathiesen, Inger Hee Mabuza

AU - Salem, Mohammad

AU - Gerstoft, Jan

AU - Gaardbo, Julie Christine

AU - Obel, Niels

AU - Pedersen, Court

AU - Ullum, Henrik

AU - Nielsen, Susanne Dam

AU - Hansen, Ann-Brit Eg

PY - 2017/4/11

Y1 - 2017/4/11

N2 - BACKGROUND: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand (RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-naïve HIV-infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.METHODS: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.RESULTS: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to -5) at week 24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.CONCLUSION: In this study there was no indication that the accelerated bone loss after cART initiation was mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial weeks after initiation of cART.TRIAL REGISTRATION: Clinical-Trial.gov . id NCT00135460 , August 25, 2005. The study was approved by the Danish Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.

AB - BACKGROUND: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand (RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-naïve HIV-infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.METHODS: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.RESULTS: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to -5) at week 24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.CONCLUSION: In this study there was no indication that the accelerated bone loss after cART initiation was mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial weeks after initiation of cART.TRIAL REGISTRATION: Clinical-Trial.gov . id NCT00135460 , August 25, 2005. The study was approved by the Danish Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.

KW - Adult

KW - Anti-HIV Agents

KW - CD4-Positive T-Lymphocytes

KW - Drug Therapy, Combination

KW - Female

KW - HIV Infections

KW - Humans

KW - Lymphocyte Count

KW - Male

KW - Middle Aged

KW - RANK Ligand

KW - Journal Article

U2 - 10.1186/s12879-017-2368-y

DO - 10.1186/s12879-017-2368-y

M3 - Journal article

C2 - 28399815

SN - 1471-2334

VL - 17

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

M1 - 262

ER -